Head-to-head · WeighScore
Aurelius Health Group vs Meto
The verdict
Meto takes it — 62/100 to 60.8/100, but only just.
Meto grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Meto is an insurance-accepting metabolic telehealth platform offering compounded semaglutide and compounded tirzepatide, prescribed after clinician-ordered lab work. Aurelius Health Group is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aurelius Health Group | Meto |
|---|---|---|
| WeighScore | 60.8/100 | 62/100 |
| Grade | C | C |
| Scorecard rank | #311 | #278 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | $199/mo (microdose tier, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #311 · C
Strengths
- Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
- LegitScript Certified
- Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
- Unusually candid about the limited evidence base for microdosing
Where it loses points
- The advertised $89 is a first-month new-patient rate; every month after it is $199
- This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
- No state count is published, only 'most US states', confirmed at intake
- The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
- Compounded tirzepatide is not an FDA-approved finished product
Graded #278 · C
Strengths
- Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
- Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
- Matches patients with endocrinologists and obesity medicine specialists within minutes
- Offers compounded semaglutide and tirzepatide with board-certified physician oversight
- Handles all prior-auth paperwork; provider location pages exist for all 50 US states
Where it loses points
- Medication pricing fully gated behind quiz — no public cash price for sema or tirz
- Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
- No LegitScript certification or named compounding pharmacy found on any public page
- Company leadership and clinical team not disclosed publicly
- Self-pay cash pricing exists per site copy but is not published anywhere
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.